Comparative Safety of the BNT162b2 Messenger RNA COVID-19 Vaccine vs Other Approved Vaccines in Children Younger Than 5 Years

Autor: Nicole Toepfner, Wolfgang C. G. von Meißner, Christoph Strumann, Denisa Drinka, David Stuppe, Maximilian Jorczyk, Jeanne Moor, Johannes Püschel, Melanie Liss, Emilie von Poblotzki, Reinhard Berner, Matthias B. Moor, Cho-Ming Chao

Publikováno v: Matthias Moor
Toepfner, Nicole; von Meißner, Wolfgang C G; Strumann, Christoph; Drinka, Denisa; Stuppe, David; Jorczyk, Maximilian; Moor, Jeanne; Püschel, Johannes; Liss, Melanie; von Poblotzki, Emilie; Berner, Reinhard; Moor, Matthias B; Chao, Cho-Ming (2022). Comparative Safety of the BNT162b2 Messenger RNA COVID-19 Vaccine vs Other Approved Vaccines in Children Younger Than 5 Years. JAMA Network Open, 5(10), e2237140. American Medical Association 10.1001/jamanetworkopen.2022.37140

ImportanceSARS-CoV-2 vaccines are authorized for use in most age groups. The safety of SARS-CoV-2 vaccines is unknown in children younger than 5 years.ObjectiveTo retrospectively evaluate the safety of the BNT162b2 vaccine used off-label in children

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fd1922090040bc016ef79931a4edd87